Horizon Therapeutics Public Limited Company (HZNP) Financial Analysis & Valuation | Quarter Chart
Horizon Therapeutics Public Limited Company (HZNP)
HZNPPrice: $116.3
Fair Value: 🔒
🔒score
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Infl... more
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, deve... more
Description
Shares
| Market Cap | $26.60B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | IE | CEO | Timothy P. Walbert |
| IPO Date | 2011-07-28 | CAGR | — |
| Employees | 2,190 | Website | www.horizontherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.94% | Total Yield | 0.94% |
HZNP chart loading...
Fundamentals
Technicals
| Enterprise Value | $23.62B | P/E Ratio | 61.86 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 7.33 | P/B Ratio | 5.25 |
| P/CF Ratio | 21.18 | P/FCF Ratio | 23.51 |
| EPS | $1.88 | EPS Growth 1Y | -42.28% |
| EPS Growth 3Y | -23.31% | EPS Growth 5Y | — |
| Revenue Growth 1Y | -4.42% | Gross Margin | 0.75% |
| Operating Margin | 0.17% | Profit Margin | 0.14% |
| ROE | 0.11% | ROA | 0.06% |
| ROCE | 0.08% | Current Ratio | 3.85 |
| Quick Ratio | 3.67 | Cash Ratio | 2.48 |
| Debt/Equity | 0.51 | Interest Coverage | 7.38 |
| Altman Z Score | 5.08 | Piotroski Score | 8 |
View Horizon Therapeutics Public Limited Company financial charts →